(MENAFN) Martin Shkreli, a former director of a drug company, who forced a life-saving medicine's price to be raised excessively, has been excluded from the industry for the rest of his life.
Judge Denise Cote ruled on Friday that Shkreli must repay USD64.6 million (£47 million) in earnings he made from his plan.
She found that Mr Shkreli's actions were in violation of anti-monopoly laws. Mr. Shkreli is already incarcerated after scamming shareholders.
However, this judgement is based on his decision in 2015 to bump up the price of Daraprim, a long-established medicine used to cure toxoplasmosis, from USD13.50 to USD750 in one day, nearly 4,000 percent higher.
MENAFN15012022000045012476ID1103543412
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.